Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2

Immunotherapies targeting programmed cell death protein 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), dramatically improve the survival of melanoma patients. However, only ∼40% of treated patients demonstrate a clinical response to single-agent anti-PD-1 therapy. An intact tumor re...

Full description

Bibliographic Details
Main Authors: Na Luo, Luigi Formisano, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Phillip T. Dean, Susan R. Opalenik, Melinda E. Sanders, Rebecca S. Cook, Carlos L. Arteaga, Douglas B. Johnson, Justin M. Balko
Format: Article
Language:English
Published: Taylor & Francis Group 2018-06-01
Series:OncoImmunology
Subjects:
ifn-γ
jak/stat
ptpn2
checkpoint immunotherapy
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1438106

Internet

http://dx.doi.org/10.1080/2162402X.2018.1438106

Similar Items